Efficacy of Infliximab Versus Vedolizumab in the Management of Immune Checkpoint Inhibitor-Induced Colitis: A Systematic Review and Meta-Analysis
World Journal of Oncology · 2025-08 · 16 (4) · 331-341
DOI: 10.14740/wjon2613 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift World Journal of Oncology, 2025-08. Verfasst von Shreya Shambhavi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Rutgers Health/Community Medical Center, Toms River, NJ, USA. Die Arbeit wurde bisher 5-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Rutgers Health/Community Medical Center, Toms River, NJ, USA.
- Mahatma Gandhi Memorial Medical College, Jamshedpur, Jharkhand, India.
- Mary Washington Healthcare, Fredericksburg, VA, USA.
- Department of Medicine, Rowan-Virtua University School of Osteopathic Medicine, Stratford, NJ 08084, USA.
- Nazareth Hospital, Trinity-Health Mid-Atlantic, Philadelphia, PA, USA.
- Henry Ford St. John Hospital, Detroit, MI, USA.
Zitieren
APA
Shambhavi, S., Singh, H., Ramaprasad, G., Khikmatov, M., Vankeshwaram, V., Ashish, K., Valladares, C., Bhatt, T., & Cohen, S. D. (2025). Efficacy of Infliximab Versus Vedolizumab in the Management of Immune Checkpoint Inhibitor-Induced Colitis: A Systematic Review and Meta-Analysis. World Journal of Oncology, 16(4), 331-341. https://doi.org/10.14740/wjon2613
Vancouver
Shambhavi S, Singh H, Ramaprasad G, Khikmatov M, Vankeshwaram V, Ashish K, et al. Efficacy of Infliximab Versus Vedolizumab in the Management of Immune Checkpoint Inhibitor-Induced Colitis: A Systematic Review and Meta-Analysis. World Journal of Oncology. 2025;16(4):331-341. doi:10.14740/wjon2613
BibTeX
@article{Shambhavi2025,
author = {Shambhavi, Shreya and Singh, Harmanjeet and Ramaprasad, Ganesh and Khikmatov, Murod and Vankeshwaram, Varun and Ashish, Kumar and Valladares, Carlos and Bhatt, Tanushree and Cohen, Seth D},
title = {Efficacy of Infliximab Versus Vedolizumab in the Management of Immune Checkpoint Inhibitor-Induced Colitis: A Systematic Review and Meta-Analysis},
journal = {World Journal of Oncology},
year = {2025},
volume = {16},
number = {4},
pages = {331--341},
doi = {10.14740/wjon2613}
}
EUVIMED